We can help vaccines keep up with the mutating coronavirus by doubling down on preventive measures.
Academic rigour, journalistic flair
Articles on AstraZeneca vaccine
Displaying 101 - 120 of 154 articles
Over 130 million doses have already been administered worldwide. It’s early days, but the signs are promising in places like Israel and the UK.
Yes, this news is disappointing - but it’s also no great surprise given how quickly this virus mutates. And it doesn’t yet mean Australia should bin its plan to use the AstraZeneca vaccine.
Vaccine developers pledge to create boosters that can better handle the new variants of the virus, and new data gives reassurance on the Oxford vaccine.
New trial data appears to support pushing back the second dose to 12 weeks.
A growing list of countries is recommending that the AstraZeneca vaccine only be use in those younger than 65.
It’s going to be a huge logistical challenge.
A recommendation from a German vaccine advisory body not to give the AstraZeneca vaccine to people aged over 65 has caused concern. But we should interpret this advice with caution.
Tensions run high as EU vaccine deliveries fall behind schedule, while new vaccines are being created to handle mutant viral strains.
The vaccine is still very likely to be protective in over-65s, even if efficacy in this age group is unknown.
Results from individual studies are very precise, and not always the best grounds for making policy decisions.
Lower than expected deliveries of AstraZeneca vaccines are exposing the bloc’s slow rollout.
Production limits the rate at which vaccines can be rolled out, and is at the heart of the current disagreements between the UK and EU.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
Australia is set to get the green light to roll out the Pfizer vaccine any day now. There is a complex process behind this.
With richer countries having bought up most of the leading western vaccines, others are looking to India, China and Russia for supplies.
Critics of the South African government argue that it has done too little too late to secure vaccines, and that it doesn’t have a proper plan in place for rollout.
Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
In our first weekly update on COVID vaccines, we consider how roll-out plans are being tweaked and when it’s likely we’ll start to see vaccines having an impact.
What normally takes decades has been achieved in 12 months, without cutting corners.
Top contributors
-
Professorial Fellow, University of Canberra
-
Professor of Medicine, University of East Anglia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Senior Research Fellow in Global Health, University of Southampton
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
General Practitioner, PhD Candidate, Bond University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Immunology, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Chair in Epidemiology, Deakin University
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Professor and Director of the Clinical Anatomy Learning Centre, Lancaster University
